HILLEVAX
HilleVax is a biopharmaceutical company that focuses on the development and commercialization of novel vaccines. HilleVax was founded in 2021 and was headquartered in Boston, Massachusetts.
HILLEVAX
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2021-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.hillevax.com
Total Employee:
11+
Status:
Active
Contact:
(617) 213-5054
Email Addresses:
[email protected]
Total Funding:
135 M USD
Technology used in webpage:
Wordpress Plugins Sitelinks Search Box Microsoft Azure DNS Google Analytics 4 Page Links To Adobe Marketing Cloud Adobe Audience Manager JobVite
Similar Organizations
Adcentrx Therapeutics
Adcentrx is a biotechnology company focused on therapeutic development for cancer and other life-threatening diseases
Akeso Biopharma
Akeso Biopharma is a biopharmaceutical company committed to the discovery, development, and commercialization of therapies.
AmVac
AmVac is a biopharmaceutical company focusing on the development and commercialization of immune therapies and prophylactic vaccines.
Animal Bioscience
Animal Bioscience is a pet platform.
Captura Biopharma
Captura Biopharma is an emerging biotechnology company engaged in the development and commercialization of heavy metal chelators.
Day One Biopharmaceuticals
Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Emalex Biosciences, Inc.
Emalex Biosciences is a biopharmaceutical company dedicated to the development of new and novel treatments.
Entera Bio
Entera Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel drug delivery platform.
Equilibre
Equilibre is a biopharmaceuticals corporation developing differentiated and novel therapeutic candidates.
Mirum Pharmaceuticals
Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
PeptiVir
PeptiVir, Inc., a biopharmaceutical company, engages in the development and commercialization of synthetic peptide-based vaccines for the
PhytoChem Pharmaceuticals
PhytoChem is a pharmaceutical company focused on the research, development, and commercialization of novel compounds.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
resTORbio
resTORbio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics.
Stealth BioTherapeutics
Stealth BioTherapeutics is a clinical-stage biotechnology company focused on genetic diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Deerfield
Deerfield investment in Venture Round - HilleVax
Abingworth
Abingworth investment in Venture Round - HilleVax
Greenspring Associates
Greenspring Associates investment in Venture Round - HilleVax
RA Capital Management
RA Capital Management investment in Venture Round - HilleVax
Catalys Pacific
Catalys Pacific investment in Venture Round - HilleVax
Richard King Mellon Foundation
Richard King Mellon Foundation investment in Venture Round - HilleVax
Qiming Venture Partners USA
Qiming Venture Partners USA investment in Venture Round - HilleVax
Perceptive Advisors
Perceptive Advisors investment in Venture Round - HilleVax
BVF Partners
BVF Partners investment in Venture Round - HilleVax
Lightspeed Venture Partners
Lightspeed Venture Partners investment in Venture Round - HilleVax
Official Site Inspections
http://www.hillevax.com Semrush global rank: 4.57 M Semrush visits lastest month: 2.27 K
- Host name: 23.185.0.1
- IP address: 23.185.0.1
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "HilleVax"
About Us - HilleVax
Rob Hershberg, M.D., Ph.D., is a Co-Founder of HilleVax, President, Chief Executive Officer and chairman of the board of directors of HilleVax. Rob is a Venture Partner with Frazier Healthcare Partners and has been working with …See details»
HilleVax - Crunchbase Company Profile & Funding
Additionally, HilleVax has entered into an exclusive license agreement to acquire norovirus vaccine rights, suggesting an expansion of its product portfolio and potential market reach. Furthermore, the company is looking to offer the first …See details»
10-K - SEC.gov
Dec 31, 2022 incorporation or organization) (I.R.S. Employer Identification No.) 75 State Street, Suite 100 - #9995, Boston, Massachusetts. 02109 ... HilleVax, to continue the development of …See details»
HilleVax - LinkedIn
HilleVax is a biopharmaceutical company focused on the development and commercialization of novel vaccines. Our initial program, HIL-214, is a virus-like particle (VLP) based vaccine …See details»
10-Q - SEC.gov
Mar 31, 2024 HILLEVAX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware. 85-0545060 (State or other jurisdiction of. incorporation or organization) (I.R.S. Employer …See details»
FORM 10-Q - SEC.gov
Sep 30, 2022 HILLEVAX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware. 85-0545060 (State or other jurisdiction of. incorporation or organization) (I.R.S. Employer …See details»
HilleVax Company Profile 2024: Stock Performance & Earnings
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus …See details»
HilleVax Company Profile: Overview and Full News Analysis
HilleVax, based in Massachusetts, is a company focused on advancing the development of a vaccine to protect against norovirus infection, which is the most common viral cause of acute …See details»
HilleVax, Inc. Company Profile | Boston, MA - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for HilleVax, Inc. of Boston, MA. Get the latest business insights from Dun & Bradstreet.See details»
20 Things You Didn’t Know about HilleVax Inc - Money Inc
Dec 7, 2022 Hillevax Inc is a pharmaceutical company that caught the eye of investors with its recent IPO. It’s an American startup headquartered in Boston, Massachusetts, It’s a solid and …See details»
HilleVax Announces Reduction in Force - FT.com
Jul 31, 2024 HilleVax is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. Its initial programs, HIL-214 and HIL-216, are virus-like …See details»
HilleVax - Abingworth LLP
HilleVax is a biopharmaceutical company focused on the development and commercialisation of novel vaccine candidates. Its initial programme, HIL-214, is a virus-like particle (VLP) based …See details»
HilleVax, Inc. (HLVX) Stock Price, News, Quote & History - Yahoo …
HilleVax, Inc. Overview Biotechnology / Healthcare HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in …See details»
HilleVax, Inc. Announces Workforce Reduction and Leadership
Dec 5, 2024 HilleVax, Inc. is reducing its workforce by 70% to cut costs while continuing to pursue the development of its norovirus vaccine and other strategic opportunities. This move …See details»
EX-99.1 - SEC.gov
About HilleVax . HilleVax is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. Its initial program, HIL-214, is a virus-like particle (VLP) …See details»
HilleVax Reports Third Quarter 2024 Financial Results and …
Nov 7, 2024 HilleVax is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. Its initial programs, HIL-214 and HIL-216, are virus-like …See details»
HilleVax (HLVX) Earnings Date and Reports 2025 - MarketBeat
3 days ago HilleVax posted Q3 2024 earnings on November 7, 2024, reporting an EPS of -$0.52, which missed analysts' consensus estimates of -$0.42 by $0.10. With a trailing EPS of …See details»
Hillevax Inc Salary for Chief Operating Officer & Co-Founder
The average annual Hillevax Inc Salary for Chief Operating Officer & Co-Founder is estimated to be approximately $524,950 per year. ... CIEE is a non-profit study abroad and intercultural …See details»
HilleVax - Company Profile - Tracxn
Oct 12, 2024 HilleVax ranks 5th among 78 active competitors. 21 of its competitors are funded while 17 have exited. Overall, HilleVax and its competitors have raised over $1.68B in funding …See details»